Seviol Tablet 10/40 mg
Amlodipine Besylate · Olmesartan Medoxomil
Prescription medication · Combination
Junghun Pharm. Co., Ltd.
MFDS item code 201803057 · Approved 2018.07.24
This product's status changed to Expired on 2023.07.24. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not controlled with monotherapy
This medication is used for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled with monotherapy of amlodipine or olmesartan medoxomil. It helps patients with hypertension effectively lower their blood pressure, reducing the risk of cardiovascular disease.
Take 1 tablet once daily with water, regardless of meals. It is recommended to take the tablet at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with intravascular volume depletion: In patients who may have intravascular volume depletion (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ∘Elderly patients: Treatment should generally be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in elderly patients.
The safety and efficacy in pediatric patients under 18 years of age have not been established.
This medication can cause serious harm to the fetus and newborn during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used in individuals who are allergic to any of the ingredients, are pregnant or breastfeeding, have severe liver disease, aortic stenosis, biliary obstruction, are undergoing renal dialysis, are in shock, certain diabetic patients, and patients with moderate to severe renal impairment. Blood pressure should be monitored carefully in patients with low blood pressure due to dehydration or electrolyte deficiency, particularly in the early stages of treatment, as their blood pressure may drop too low. If hypotension occurs, appropriate measures should be taken. Due to the risk of rapid vasodilation leading to hypotension, caution should be taken in patients with severe aortic stenosis. Patients with severe obstructive coronary artery disease may have an increased risk of angina or myocardial infarction when taking this medication, warranting extra caution. Use with caution in patients with heart failure, as renal function may deteriorate and lead to renal failure, requiring regular monitoring. Patients with reduced liver function may be affected by the metabolism of this drug, necessitating dosage adjustments and careful supervision. While on this medication, regular checks of blood pressure, renal function, electrolyte levels, etc., are essential, especially due to the risk of hyperkalemia, necessitating careful monitoring of potassium levels. This medication may interact with other antihypertensive agents or specific medications. If you are taking other medications, make sure to inform your healthcare provider. Breastfeeding women are advised to stop either breastfeeding or taking this medication, as it may pass into breast milk and cause side effects in infants. The safety and efficacy in children under 18 years of age have not been established, so use is not recommended. The elderly may experience altered effects and side effects due to decreased renal and liver function and should start with a low dose and be treated with caution. In case of overdose, there may be a drop in blood pressure and cardiac function abnormalities, and immediate medical attention is required, with close observation of blood pressure and cardiac function. This medication should be stored away from direct sunlight and moisture, in a tightly closed container, and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius.
Reddish-brown round film-coated tablets
30 tablets (10 tablets/PTP x 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Amlodipine Besylate · Olmesartan Medoxomil
Prescription medication · Combination
Junghun Pharm. Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.